Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Kinase inhibitors are molecules that block the activity of kinases. Kinases are a specific class of enzymes. They are extremely important in signal transduction processes in the human body meaning that they actually regulate most of the physiological processes that take place in the body.

7 May 2013

Neuroperspective reviews status and prospects of therapeutics for Parkinson's disease

NI Research, the leading publisher of independent research on the neurotherapeutics industry, has released the May issue of NeuroPerspective, which reviews the status and prospects of therapeutics for Parkinson's.

7 May 2013

NeuroPhage Pharmaceuticals raises $6.4 million in private equity financing round

NeuroPhage Pharmaceuticals, Inc., a company developing breakthrough therapies for neurodegenerative diseases, today announced that it raised $6.4 million in a private equity financing round.

6 May 2013

Discovery may lead to new treatment for neurodevelopmental, neurodegenerative disorders

A key type of human brain cell developed in the laboratory grows seamlessly when transplanted into the brains of mice, UC San Francisco researchers have discovered, raising hope that these cells might one day be used to treat people with Parkinson's disease, epilepsy, and possibly even Alzheimer's disease, as well as and complications of spinal cord injury such as chronic pain and spasticity.

5 May 2013

Gray matter atrophy underlies PD subtypes

Patients with the postural instability gait difficulty subtype of Parkinson’s disease have marked gray matter atrophy relative to those with the tremor dominant subtype, shows research.

30 Apr 2013

Schizophrenia cardiovascular risk under-recognized in primary care

UK researchers have found that despite being a major contributor to premature deaths among patients with schizophrenia, cardiovascular disease is less likely to be recorded on their primary care records than those of people without schizophrenia.

30 Apr 2013

Researchers identify how a defective protein plays central role in Giant Axonal Neuropathy

A team of international researchers led by Northwestern Medicine scientists has identified how a defective protein plays a central role in a rare, lethal childhood disease known as Giant Axonal Neuropathy, or GAN.

29 Apr 2013

CHMP recommends approval of NUEDEXTA for treatment of pseudobulbar affect

Avanir Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate), recommending NUEDEXTA be approved for the treatment of pseudobulbar affect, irrespective of neurologic cause.

29 Apr 2013

Research on alpha-synuclein protein could lead to new therapies for Parkinson's disease

A protein known to be a key player in the development of Parkinson's disease is able to enter and harm cells in the same way that viruses do, according to a Loyola University Chicago Stritch School of Medicine study.

26 Apr 2013

DBS appears to reduce caloric intake and weight loss in obese animal models

Deep brain stimulation (DBS) in a precise region of the brain appears to reduce caloric intake and prompt weight loss in obese animal models, according to a new study led by researchers at the University of Pennsylvania.

25 Apr 2013

Schizophrenia cardiovascular risk under-recognized in primary care

25 Apr 2013

Transcranial magnetic stimulation benefits in Parkinson’s disease

A course of low-frequency repetitive transcranial magnetic stimulation delivered over the supplementary motor area improves motor symptoms in patients with Parkinson’s disease, shows results from a randomized controlled trial.

25 Apr 2013

Microglia guard nerve cells and play important role in their basic function

Researcher Johan Jakobsson and his colleagues have now published their results in Nature Communications.

25 Apr 2013

Sofosbuvir is safer than interferon for hepatitis C patients, say scientists

A new drug is offering dramatic cure rates for hepatitis C patients with two subtypes of the infection -- genotype 2 and 3, say a team of scientists led by Weill Cornell Medical College researchers.

25 Apr 2013

Research: DBS may provide therapeutic relief to binge eating

Deep brain stimulation in a precise region of the brain appears to reduce caloric intake and prompt weight loss in obese animal models, according to a new study led by researchers at the University of Pennsylvania.

24 Apr 2013

Investigational treatment for ALS passes early phase clinical trial for safety

An investigational treatment for an inherited form of Lou Gehrig's disease has passed an early phase clinical trial for safety, researchers at Washington University School of Medicine in St. Louis and Massachusetts General Hospital report.

24 Apr 2013

PPMI to launch additional study to evaluate multiple potential biomarkers for Parkinson's disease

The Parkinson's Progression Markers Initiative, a landmark biomarker clinical study, has completed enrollment of its initial 600-member cohort of Parkinson's patients and controls, and will launch additional study cohorts to leverage the existing PPMI infrastructure and evaluate multiple potential biomarkers for Parkinson's disease.

24 Apr 2013

Research findings could provide a way to treat onset, progression of Parkinson's disease

The earliest signs of Parkinson's disease can be deceptively mild. The first thing that movie star Michael J. Fox noticed was twitching of the little finger of his left hand.

23 Apr 2013

Cerecor obtains exclusive, worldwide rights to NR2B receptor antagonist from Merck

Cerecor Inc, a neuroscience biotech company that develops therapies that have the potential to make a difference in diseases with high unmet medical needs, today announced that it has acquired exclusive, worldwide rights from Merck, known as MSD outside the United States and Canada, to develop and commercialize MK-0657, a small molecule NMDA receptor subunit 2B (NR2B) antagonist for all human indications, including depression.

22 Apr 2013

Non-invasive brain surgery: an interview with Dr Andres Lozano, University of Toronto

MR-guided focused ultrasound is a new technique that involves focusing 1024 beams of ultrasound through the skull to a focal point in the brain, very much like using the sun and a magnifying glass to burn a hole in a sheet of paper.

22 Apr 2013

Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

Kinase inhibitors: an interview with Jan Hoflack, CSO of Oncodesign

Neuroperspective reviews status and prospects of therapeutics for Parkinson's disease

NeuroPhage Pharmaceuticals raises $6.4 million in private equity financing round

Discovery may lead to new treatment for neurodevelopmental, neurodegenerative disorders

Gray matter atrophy underlies PD subtypes

Schizophrenia cardiovascular risk under-recognized in primary care

Researchers identify how a defective protein plays central role in Giant Axonal Neuropathy

CHMP recommends approval of NUEDEXTA for treatment of pseudobulbar affect

Research on alpha-synuclein protein could lead to new therapies for Parkinson's disease

DBS appears to reduce caloric intake and weight loss in obese animal models

Schizophrenia cardiovascular risk under-recognized in primary care

Transcranial magnetic stimulation benefits in Parkinson’s disease

Microglia guard nerve cells and play important role in their basic function

Sofosbuvir is safer than interferon for hepatitis C patients, say scientists

Research: DBS may provide therapeutic relief to binge eating

Investigational treatment for ALS passes early phase clinical trial for safety

PPMI to launch additional study to evaluate multiple potential biomarkers for Parkinson's disease

Research findings could provide a way to treat onset, progression of Parkinson's disease

Cerecor obtains exclusive, worldwide rights to NR2B receptor antagonist from Merck

Non-invasive brain surgery: an interview with Dr Andres Lozano, University of Toronto

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Parkinson's Disease News and Research

Latest Parkinson's Disease News and Research

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in